A 16-year-old girl presents with a 4-month history of pain and swelling in the right tibia. She denies trauma. On examination, there is a firm, tender swelling over the anterior tibia with overlying skin warmth. Laboratory findings show WBC 14,200/μL, ESR 55 mm/hr, and LDH 680 U/L (elevated). Plain radiographs show a lytic lesion in the diaphysis with a wide zone of transition and cortical destruction. MRI reveals a large intramedullary and extraosseous soft tissue component with heterogeneous signal intensity. What is the most appropriate next step in management?

Explanation

## Management of Suspected Ewing Sarcoma: Diagnostic Confirmation First ### Clinical Scenario Analysis **Key Point:** Before any definitive treatment is initiated, histological confirmation of the diagnosis is mandatory. A biopsy (core needle or open) must be performed to confirm Ewing sarcoma and rule out other differential diagnoses. **High-Yield:** The diagnostic algorithm for bone tumors follows a strict sequence: 1. **Imaging** (plain radiographs, MRI) → suggests diagnosis 2. **Biopsy** → confirms histology and molecular markers (t(11;22) translocation) 3. **Staging** → determines extent of disease (CT chest, bone scan, PET-CT) 4. **Treatment planning** → multimodal therapy based on stage and prognosis ### Why Biopsy Is Essential | Reason | Explanation | |--------|-------------| | **Diagnostic confirmation** | Histology shows small round cell tumor; immunohistochemistry (CD99+, FLI1+) supports diagnosis | | **Molecular testing** | EWSR1-FLI1 fusion gene (t(11;22)) is diagnostic and prognostic | | **Rule out mimics** | Lymphoma, rhabdomyosarcoma, metastatic disease, or infection must be excluded | | **Treatment planning** | Histological grade and molecular markers guide chemotherapy selection and intensity | **Clinical Pearl:** Proceeding to surgery without biopsy risks inappropriate treatment (e.g., amputation for lymphoma) and delays definitive multimodal therapy. ### Correct Management Sequence ```mermaid flowchart TD A[Clinical suspicion of Ewing sarcoma]:::outcome --> B[Imaging: Plain X-ray + MRI]:::action B --> C[Biopsy for histology & molecular testing]:::action C --> D{Ewing sarcoma confirmed?}:::decision D -->|Yes| E[Staging: CT chest, bone scan, PET-CT]:::action E --> F[Neoadjuvant chemotherapy]:::action F --> G[Surgical resection]:::action G --> H[Adjuvant chemotherapy ± radiotherapy]:::action H --> I[Long-term follow-up]:::outcome D -->|No| J[Alternative diagnosis & treatment]:::outcome ``` ### Why Each Treatment Option Is Premature Without Biopsy **Key Point:** Surgery or radiotherapy without histological confirmation is contraindicated. 1. **Wide local excision + radiotherapy alone:** Insufficient for Ewing sarcoma; requires chemotherapy for systemic disease control 2. **Amputation:** Overly aggressive and unnecessary if multimodal therapy is planned; reserved for cases with vascular compromise or failed limb-salvage attempts 3. **Neoadjuvant chemotherapy without biopsy:** Initiating chemotherapy for an unconfirmed diagnosis risks treating the wrong disease (e.g., lymphoma requires different regimens) **Mnemonic — BIOPSY FIRST:** **B**efore any **I**ntervention, **O**btain **P**athology, **S**tage, **Y**ield treatment plan ### Standard Ewing Sarcoma Treatment (After Biopsy & Staging) **High-Yield:** The multimodal approach includes: - **Neoadjuvant chemotherapy** (e.g., VIDE: vincristine, ifosfamide, doxorubicin, etoposide) for 10–12 weeks - **Surgical resection** with wide margins (limb-salvage preferred over amputation when feasible) - **Adjuvant chemotherapy** for 12–24 weeks total - **Radiotherapy** if inadequate surgical margins or high-risk features **Clinical Pearl:** This multimodal approach has improved 5-year survival from ~10% (surgery alone) to ~70% (combined therapy) for localized disease.